Clinical Trial

Endoscopic Resection for Small Rectal Neuroendocrine Tumors

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
According to clinical practice and relevant retrospective research data, both modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic mucosal resection with a ligation device(ESMR-L) were reported to be effective for the treatment of small rectal neuroendocrine tumors (NETs) . However, there is a lack of multicenter prospective studies to evaluate the advantages and disadvantages of mEMR-C and mEMR-L. mEMR-C is the modified ESMR-L without submucosal injection.
Trial Details
NCT Number NCT06901856
Lead Sponsor Guangdong Provincial People's Hospital
Conditions Rectal Neuroendocrine Tumor
Enrollment 120 participants
Start Date 2025-03
Primary Completion 2025-12 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2025-03-30